Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00309985 · BASELINE

Baseline characteristics

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer · Source last updated 2025-12-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      397
    2. group Id
      BG001
      value
      393
    3. group Id
      BG002
      value
      790
    units
    Participants
groups
  1. description
    Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \[LHRH\] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Androgen-Deprivation Therapy and Docetaxel
  2. description
    Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \[LHRH\] agonist therapy, LHRH antagonist therapy, or surgical castration).
    id
    BG001
    title
    Androgen-Deprivation Therapy Alone
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          36
          upper Limit
          88
          value
          64
        2. group Id
          BG001
          lower Limit
          39
          upper Limit
          91
          value
          63
        3. group Id
          BG002
          lower Limit
          36
          upper Limit
          91
          value
          63
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          397
        2. group Id
          BG001
          value
          393
        3. group Id
          BG002
          value
          790
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
All randomized patients
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      397
    2. group Id
      BG001
      value
      393
    3. group Id
      BG002
      value
      790
    units
    Participants
groups
  1. description
    Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \[LHRH\] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Androgen-Deprivation Therapy and Docetaxel
  2. description
    Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \[LHRH\] agonist therapy, LHRH antagonist therapy, or surgical castration).
    id
    BG001
    title
    Androgen-Deprivation Therapy Alone
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          36
          upper Limit
          88
          value
          64
        2. group Id
          BG001
          lower Limit
          39
          upper Limit
          91
          value
          63
        3. group Id
          BG002
          lower Limit
          36
          upper Limit
          91
          value
          63
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          397
        2. group Id
          BG001
          value
          393
        3. group Id
          BG002
          value
          790
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
All randomized patients

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice